Ebbers Sabine, Creemers Johan W T, Lotgering Fred K
Universitair Medisch Centrum St Radboud, afd. Verloskunde & Gynaecologie, Nijmegen, The Netherlands.
Ned Tijdschr Geneeskd. 2009;153:A138.
To compare the efficacy of sulprostone and mifepristone/misoprostol when used for termination of pregnancy (TOP) in the 2nd trimester.
Comparative retrospective cohort study.
Data were collected on all women whose pregnancies were terminated in the 2nd trimester, in the presence of severe fetal defects, between 1996 and 2007 at the Radboud University Nijmegen Medical Centre, the Netherlands. From the start of 1996 until the end of 2001 TOPs were performed using sulprostone. In 2001 the treatment was switched to the combination mifepristone/misoprostol. The primary outcome measure was the time interval between the initiation of prostaglandin medication and the birth of the infant.
158 patients met the inclusion criteria: 51 women were treated with sulprostone, 107 women with mifepriston/misoprostol. The duration of treatment in the mifepristone/misoprostol group (median 8.7 hours, range: 1.1-72.0 hours) was significantly shorter than in the sulprostone group (median 21.3 hours, range: 7.8-265.0 hours). In the mifepristone/misoprostol group significantly more women (94%) delivered within 24 hours than in the sulprostone group (55%). In the mifepristone/misoprostol group anti-emetics and pain relief were given significantly less often than in the sulprostone group 5 versus 12% and 54 versus 90%, respectively). There was no statistically significant difference in the number of women with post partum blood loss (6 versus 6%), (suspected) placental remnants (33 versus 43%) or fever (12 versus 4%).
In termination of pregnancy in the 2nd trimester mifepristone/misoprostol was more effective than sulprostone. Given the disadvantages of sulprostone in comparison with mifepristone/misoprostol, sulprostone no longer deserves a place in termination of pregnancy in the 2nd trimester.
比较磺前列酮与米非司酮/米索前列醇用于中期妊娠终止(TOP)的疗效。
比较性回顾性队列研究。
收集1996年至2007年期间在荷兰拉德堡德大学奈梅亨医学中心因严重胎儿缺陷而在中期终止妊娠的所有女性的数据。从1996年初到2001年底,使用磺前列酮进行中期妊娠终止。2001年治疗改为米非司酮/米索前列醇联合用药。主要结局指标是前列腺素用药开始至婴儿出生的时间间隔。
158例患者符合纳入标准:51例女性接受磺前列酮治疗,107例女性接受米非司酮/米索前列醇治疗。米非司酮/米索前列醇组的治疗时间(中位数8.7小时,范围:1.1 - 72.0小时)明显短于磺前列酮组(中位数21.3小时,范围:7.8 - 265.0小时)。米非司酮/米索前列醇组在24小时内分娩的女性明显多于磺前列酮组(94%对55%)。米非司酮/米索前列醇组使用止吐药和止痛药物的频率明显低于磺前列酮组(分别为5%对12%和54%对90%)。产后出血(6%对6%)、(疑似)胎盘残留(33%对43%)或发热(12%对4%)的女性数量无统计学显著差异。
在中期妊娠终止中,米非司酮/米索前列醇比磺前列酮更有效。鉴于磺前列酮与米非司酮/米索前列醇相比存在劣势,磺前列酮在中期妊娠终止中不再值得使用。